NCT03968991 (VISIODOL) is a NA clinical trial of VISIODOL® (Diagnostic tool) in Visual Deficiency, sponsored by University Hospital, Clermont-Ferrand.

Who is sponsoring NCT03968991?

NCT03968991 is sponsored by University Hospital, Clermont-Ferrand.

What drugs are being tested in NCT03968991?

Interventions in NCT03968991: VISIODOL® (Diagnostic tool).

What condition does NCT03968991 study?

NCT03968991 studies Visual Deficiency, Congenital Blindness, Acquired Blindness.

Is NCT03968991 still recruiting?

NCT03968991 is currently terminated. Last updated 13 March 2023.

Last reviewed 2023-03-13 · How we verify

NCT03968991: VISIODOL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

VISIODOL: Validation of the VISIODOL® Scale

Terminated NA Last updated 13 March 2023

What this trial tests

NA trial testing VISIODOL® (Diagnostic tool) in Visual Deficiency in 37 participants. Terminated before completion.

Timeline

18 June 2019

Primary endpoint
28 December 2020

28 December 2020

Quick facts

Lead sponsor	University Hospital, Clermont-Ferrand
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	37
Start date	18 June 2019
Primary completion	28 December 2020
Estimated completion	28 December 2020
Sites	1 location across France

Drugs / interventions tested

VISIODOL® (Diagnostic tool)

Conditions studied

Visual Deficiency — all drugs for Visual Deficiency →
Congenital Blindness — all drugs for Congenital Blindness →
Acquired Blindness — all drugs for Acquired Blindness →

Sponsor

University Hospital, Clermont-Ferrand

Who can join

Adults 18 to 60, any sex, with Visual Deficiency or Congenital Blindness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to validate the VISIODOL® scale for screening of pain in people with visual impairment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A tactile pain evaluation scale for persons with visual deficiencies.
Pickering G, Morel V, Goubayon J, Touron A, et al · · 2023 · PMID 36809402 · DOI 10.1093/pm/pnad013

Verify or expand the search:

Other University Hospital, Clermont-Ferrand trials

Trials by the same sponsor.

NCT07179276 — Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock · NA · recruiting
NCT07476768 — PAINDYS_Characterizing Pain in Fibrous Dysplasia of Bone/McCune-Albright Syndrome: an Exploratory Pilot Study · NA · not yet recruiting
NCT07439146 — Risk of Pneumonia in Intubated Patients in Emergency Situations · not yet recruiting
NCT07427537 — Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients · NA · recruiting
NCT07330856 — Evaluation of Treatments for Dry or Productive Cough · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03968991 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Clermont-Ferrand
Last refreshed: 13 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03968991.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing